Carfentanil Was an Elephant Sedative. Now It's a Human Drug Problem

In 1974, Janssen Pharmaceuticals chemists synthesized a compound so potent a few micrograms immobilized an elephant or rhinoceros. Marketed as Wildnil for wildlife anesthesia, carfentanil was used for decades to tranquilize large animals. Commercial production ended in 2003, and the drug vanished from veterinary supply chains. For years, it seemed destined to remain a historical footnote in veterinary pharmacology.

However, in recent years, carfentanil has reemerged as a clandestinely-manufactured powder infiltrating human drug markets. Its clinical danger lies in its extreme potency. According to the DEA and investigative reporting, most illicit carfentanil originates from Chinese underground laboratories. Mexican drug trafficking organizations import the finished product or precursor chemicals, and then distribute to the United States and Canada.

Carfentanil is about 10,000 times more potent than morphine and 100 times more potent than fentanyl. The margin between intoxication and death is vanishingly small, particularly with polysubstance use. As clinicians have observed, carfentanil can rapidly cause death. Naloxone (Narcan) reversal must be swift and often requires repeated or high dosing with close monitoring. The interval between exposure and death may be as short as minutes.

Carfentanil has been detected mixed with fentanyl powder, heroin, and cocaine. It is also pressed into counterfeit oxycodone “M30” tablets, markedly increasing the risk of unintentional ingestion by exploiting the visual credibility of a familiar pharmaceutical. Exposure to carfentanil combined with benzodiazepine sedatives blunts protective airway reflexes, complicating reversal. Overdose presentations can confuse emergency responders, with prolonged sedation despite naloxone administration, recurrent hypoventilation, and atypical toxicology screens.

For years, synthetic opioids like nitazenes (isotonitazene, metonitazene, and protonitazene) appeared as clandestinely-manufactured compounds. Many were produced in Chinese laboratories, entering Western drug markets as fentanyl substitutes or additives. Their potency rivaled or exceeded fentanyl, contributing to clusters of severe overdoses. However, regulatory actions and law-enforcement pressure in China reduced the open manufacture and export of many nitazene compounds. But as the supply of these ultra-potent opioids contracted, another emerged: carfentanil. What distinguishes carfentanil is its potency markedly compresses the interval between drug use and respiratory arrest.

Individuals believing they are ingesting oxycodone—or even fentanyl—can unknowingly consume carfentanil. Monitoring of online discussions, including Reddit forums tracked by the National Drug Early Warning System (NDEWS), also suggests that carfentanil is sometimes sought by highly-tolerant users, but also appears as a lethal adulterant in street opioids and counterfeit “M30” pills.

CDC reports documented a sevenfold increase in carfentanil-involved deaths between early 2023 and mid-2024. The DEA reported detecting carfentanil in at least 37 states by late 2025, demonstrating its widespread geographic dissemination.

Counterfeit Tablets

In 2025, the DEA's Seattle Field Division seized 50,000-plus counterfeit pills containing carfentanil, while a Los Angeles operation uncovered over 600,000 tablets. State-level alerts reinforce these findings; for example, authorities in Montana reported thousands of carfentanil-positive counterfeit pills in one county. Taken together, these events indicate deliberate incorporation of carfentanil into bulk illicit products rather than sporadic contamination. They also underscore why clinicians should be cautious about relying on patient-reported substance identity.

Carfentanil vs. Fentanyl: Potency and Lethality

Source: with permission of Mark Gold, MD

Nonfatal and Fatal Carfentanil Overdoses

Between January 1, 2023, and January 31, 2026, NDEWS documented 4,515 hospital emergency-room encounters involving nonfatal carfentanil overdoses. More than 85 percent of these encounters occurred in Northeastern states, with substantially lower proportions elsewhere. This pronounced regional clustering suggests episodic, geographically concentrated supply chain penetration, not a uniform national distribution. For clinicians in heavily-affected regions—particularly in emergency medicine, hospital medicine, and addiction medicine—this concentration highlights a need for heightened vigilance, adequate naloxone availability, and systems-level readiness for abrupt surges.

Postmortem findings commonly reveal co-detection of carfentanil with fentanyl, benzodiazepines, stimulants, and other substances, reflecting polysubstance exposure. Central nervous system depressants amplify respiratory suppression, while stimulants may initially mask sedation or create a misleading early clinical picture before an abrupt collapse. In practical terms, clinicians should anticipate polysubstance abuse and focus on immediate life-threatening issues: airway, ventilation, oxygenation, and hemodynamic stability.

Addiction Essential Reads

Know You’re Addicted but Not Ready to Change?

What Does It Mean to Own Your Addiction?

Large-scale clinical urine drug testing adds another warning. National laboratory datasets showed an increase in carfentanil detection from 2023 through mid-2025, followed by a decline through early 2026. However, detection in urine does not necessarily indicate intentional use; adulteration of fentanyl or counterfeit pills may lead to inadvertent ingestion. Many individuals have no idea what drugs they consume; consequently, clinical decision-making must rely on physiology and presentation rather than presumed identity of a drug.

Some people describe a rapid escalation of drug tolerance following exposure, noting that fentanyl or pharmaceutical opioids that were subsequently consumed produced diminished effects from the recent past. Others recount severe withdrawal and difficulty transitioning to treatment medications such as buprenorphine. While anecdotal, these experiences are pharmacologically plausible. The key is recognizing that clinical consequences of ultra-potent opioids extend beyond the acute overdose event; they may also shape subsequent withdrawal trajectories and treatment transitions.

Test Strips May Not Work for the Most Potent Opioid Adulterants- Carfentanil or Cychlorphine

Some fentanyl test strips and immunoassays exhibit limited cross-reactivity with carfentanil or cychlorphine, meaning a negative result does not reliably exclude its presence. Multiple states have raised the alarm in the past month about cychlorphine, a synthetic opioid tied to several dozen recent overdoses that is far stronger than fentanyl and weaker than carfentanil. Cychlorphine is 10 times stronger than fentanyl, and a new class of synthetic opioids is making its way into the U.S. illicit drug supply.

Conclusion

Carfentanil has re-emerged as a clandestinely-manufactured synthetic opioid that has infiltrated human drug markets. It was identified in at least 37 states by late 2025. Chinese clandestine labs manufacture carfentanil and Mexican drug cartels distribute it episodically into regional drug supplies, followed by abrupt spikes in morbidity and mortality among users. A negative fentanyl screen does not exclude exposure. Carfentanil represents an extreme expression of the synthetic opioid crisis: a compound designed for elephants now appearing in counterfeit drugs and representing a major death threat among illicit opioid users.